A Phase I/II Study of CR011-vcMMAE in Patients With Locally Advanced or Metastatic Breast Cancer

Trial Profile

A Phase I/II Study of CR011-vcMMAE in Patients With Locally Advanced or Metastatic Breast Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2015

At a glance

  • Drugs Glembatumumab vedotin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Biomarker
  • Sponsors CuraGen Corporation
  • Most Recent Events

    • 06 Jun 2010 Primary endpoint 'Progression free survival rate' has been met in the phase II portion of the trial, according to a Celldex Therapeutics media release.
    • 06 Jun 2010 Results were presented at the 46th Annual Meeting of ASCO, according to a Celldex Therapeutics media release.
    • 14 Dec 2009 Status changed from active, no longer recruiting to completed, according to a Celldex Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top